Vaccines Helped GSK Post Strong Q1 Results Ahead Of RSV Approval
Looks Ahead To Second Season Data
Executive Summary
Increased disease awareness and the IRA should help boost the RSV prevention market for older adults, said GSK CEO Emma Walmsley, ahead of a US approval decision early next month, as the firm’s vaccines division helped push a strong Q1 performance. Other deals are also ‘in the hopper.’
You may also be interested in...
GSK Points To Merck’s Gardasil Success In Deal With Zhifei For Shingrix
The British drug maker hopes the partnership for the Chinese market will accelerate its efforts to reach its goal of £4bn or more in sales of Shingrix by 2026.
New Therapeutic Areas Ignite Investor Interest Amid Pandemic Reset
Investor attention is turning increasingly to new products and new areas of growth like obesity, Alzheimer’s disease and RSV as big blockbusters face increasing competitive pressure.
GSK Sees Blockbuster Chronic Cough Opportunity With $2bn Bellus Buyout
GSK has unveiled another targeted acquisition – of Bellus – that it hopes will bolster its presence in specialist respiratory medicine.